Back to Search
Start Over
Repeat mediastinoscopy in all its indications: experience with 96 patients and 101 procedures
- Source :
- European Journal of Cardio-Thoracic Surgery. 39:1022-1027
- Publication Year :
- 2011
- Publisher :
- Oxford University Press (OUP), 2011.
-
Abstract
- Objective: To evaluate the accuracy of repeat mediastinoscopy (reMS) in all its indications, and to analyse survival in the group of patients who underwent induction chemotherapy or chemoradiotherapy for pathologically proven stage III-N2 non-small-cell lung cancer (NSCLC). Methods: From July 1992 to February 2009, 96 patients (87 men; median age: 61.3 years), underwent 101 reMSs (five patients required a second reMS) for the following indications: restaging after induction therapy for pathologically proven N2 disease (84 cases), inadequate first mediastinoscopy (five), metachronous second primary (six) and recurrent lung cancer (six). Patients with N2-NSCLC, who had received induction therapy and had positive reMS, underwent definitive chemotherapy or chemoradiotherapy. Patients in whom reMS was negative underwent thoracotomy for lung resection and systematic nodal dissection (SND). SND was considered the gold standard to compare the negative results of reMS. Pathologic findings were reviewed and staging values were calculated using the standard formulas. Follow-up data were completed in January 2010, and survival analysis was performed by the Kaplan—Meier method.Results:InthegroupofreMSforrestagingafterinductiontherapy,thestagingvalues were:sensitivity0.74,specificity1,positivepredictivevalue1,negativepredictivevalue0.79anddiagnosticaccuracy0.87.Wealsodeterminedthe diagnostic value of this technique according to the type of induction treatment. In terms of accuracy, no statistically significant differences were found.Mediansurvival timeinpatientswithtruenegativereMSwas51.5months(95%confidenceinterval(CI) 0—112), and inthe combinedgroup of patients with positive and false-negative reMS, median survival time was 11 months (95% CI 7.6—14.1) ( p = 0.0001). In the group of miscellaneous indications,allstagingvalueswere1.Conclusion:ReMSisfeasibleinalltheindicationsdescribed.Afterinductiontherapy,itisausefulprocedureto selectpatientsforlungresectionwithhighaccuracy,independentlyoftheinductiontreatmentusedortheintensityofthefirstmediastinoscopy.The persistence of lymph node involvement after induction therapy has a poor prognosis. Therefore, techniques providing cytohistological evidence of nodal downstaging are advisable to avoid unnecessary thoracotomies. # 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
- Subjects :
- Adult
Male
Pulmonary and Respiratory Medicine
medicine.medical_specialty
Lung Neoplasms
medicine.medical_treatment
Antineoplastic Agents
Mediastinoscopy
Young Adult
Pneumonectomy
Carcinoma, Non-Small-Cell Lung
medicine
Humans
Stage (cooking)
Lung cancer
Neoadjuvant therapy
Aged
Neoplasm Staging
medicine.diagnostic_test
business.industry
Patient Selection
Induction chemotherapy
Chemoradiotherapy, Adjuvant
General Medicine
Middle Aged
Prognosis
medicine.disease
Chemotherapy regimen
Surgery
Treatment Outcome
Lymphatic Metastasis
Lymph Node Excision
Female
Epidemiologic Methods
Cardiology and Cardiovascular Medicine
business
Chemoradiotherapy
Subjects
Details
- ISSN :
- 10107940
- Volume :
- 39
- Database :
- OpenAIRE
- Journal :
- European Journal of Cardio-Thoracic Surgery
- Accession number :
- edsair.doi.dedup.....89d463798fdcd49749659d74e1b333fe
- Full Text :
- https://doi.org/10.1016/j.ejcts.2010.10.019